Kitov’s newest drug, NT-219, which is being developed by its majority-owned subsidiary, TyrNovo, is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. NT-219 targets IRS1/2 and STAT3 – two signal proteins that are part of an anti-cancer drug resistance mechanism. In various preclinical models where NT-219 was administered in combination with various oncology therapies, outstanding efﬁcacy in preventing acquired resistance and reversing tumor resistance was demonstrated. These therapies include EGFR Antibodies (Erbitux®), small molecular inhibitors of MEK (Mekinist®), mutated BRAF (Zelboraf®), EGFR (Tagrisso®, Tarceva®), and mTOR (Afinitor®), as well as with chemotherapy agents such as Gemcitabine, Oxaliplatin, and Docetaxel. Preliminary synergistic effects were also observed in combination with immune oncology agents such as Keytruda®.